Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 5
Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation
Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.
Video Player is loading.
Video content above is prompted by the following:
- Please comment on PARP inhibitor (PARPi) resistance. Are there promising strategies to overcome this challenge?
- PRESERVE-004 gotistobart + pembrolizumab
- Others?
- What insights can be drawn from the SOPRANO trial findings regarding the management of oligometastases or oligoprogression in ovarian cancer?
- What adverse events are most commonly seen with PARPi maintenance therapy and how do you mitigate or manage these?
